Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05689359
Other study ID # STUDY00001721
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date June 2024
Est. completion date December 1, 2025

Study information

Verified date March 2024
Source University of Arizona
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is being done to research if hydroxychloroquine can prevent chemotherapy induced peripheral neuropathy. Certain chemotherapy drugs, like paclitaxel, are known to cause neuropathy which can impact quality of life. Currently, there are no options for preventing peripheral neuropathy. In addition, there are no useful methods to assess peripheral nerve damage. This study will also explore using a study MRI of patients' feet prior to starting chemotherapy and after they have completed chemotherapy to see if there is any difference in their nerve structure.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 1, 2025
Est. primary completion date February 1, 2025
Accepts healthy volunteers No
Gender Female
Age group 21 Years and older
Eligibility Inclusion Criteria: - Patients with stage 1-3 breast cancer or gynecological cancer treated with curative intent - Age = 21 years old - No prior neurotoxic chemotherapies - No other neurotoxic chemotherapies planned during paclitaxel treatment (i.e, platinum) - Need to be treated with paclitaxel weekly x 12 doses as determined by their treating physician - Be able to undergo MR Imaging - Be willing to comply with scheduled visits, treatment plan, and MR imaging - Adequate organ function as defined as: Hematologic: Absolute neutrophil count (ANC) = 1500/mm3 Platelet count = 100,000/mm3 Hemoglobin = 9 g/dL Hepatic: Total Bilirubin = 1.5x institutional upper limit of normal (ULN) AST(SGOT)/ALT(SGPT) = 3 × institutional ULN Renal: Estimated creatinine clearance (CrCl)= 50 mL/min by Cockcroft-Gault formula Exclusion Criteria: - Stage IV cancer - CTCAE neurological function > grade 1 at baseline - Mental limitation that precludes understanding of or completion of questionnaires - History of diabetes or other neurological disorders - Preexisting peripheral neuropathy - Prior exposure to neurotoxic chemotherapy - Currently taking medication to treat or prevent neuropathy - Have non-MRI compatible metallic objects on/in body - Have metallic hardware in the lower extremity which is MR compatible however would create too much artifact for MR examination - Pregnant or lactating patients. Women of childbearing potential and sexually active men must use an effective contraception method during rreatment and for three months after completing treatment. Patients of childbearing potential must have a negative serum or urine B-hCG pregnancy test at screening. - History or current evidence of central serous retinopathy (CSR) or retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity) or macular degeneration. - QTc prolongation defined as a QTcF > 500 ms - Known glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.

Study Design


Intervention

Drug:
Hydroxychloroquine
Hydroxychloroquine will be administered at 600 mg po BID for 3 days prior to starting chemotherapy, continued during the course of chemotherapy, and for 7 days after chemotherapy.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Arizona

Outcome

Type Measure Description Time frame Safety issue
Primary Symptomatic CIPN The primary endpoint is symptomatic CIPN defined as increase in in FACT-GOG/Ntx-12 questionnaire score of greater than or equal to 3 points post-chemotherapy with hydroxychloroquine in combination with paclitaxel chemotherapy in patients with early-stage breast cancer or gynecologic malignancies. Throughout study completion, an average of 6 months
Secondary Predicting Symptomatic CIPN: FA and ADC values derived from DTI Baseline fractional anisotrophy (FA) and apparent diffusion coefficient (ADC) values derived from DTI will be used to predict symptomatic CIPN prior to starting and end of chemotherapy. Baseline
Secondary Predicting Symptomatic CIPN: change in FA and ADC Change in mean FA and ADC prior to starting and end of chemotherapy will be calculated. The mean of the change in FA and ADC values with 95% confidence intervals will be estimated (post- minus pre- chemotherapy). The baseline values and the change of FA and ADC will be used to predict the development of symptomatic CIPN using logistic regression. Baseline and 12 weeks
Secondary Predicting Symptomatic CIPN: baseline NF-L levels Baseline level of neurofilament light chain (NF-L) will be used to predict symptomatic CIPN. The baseline values will be used to predict development of symptomatic CIPN using logistic regression. Baseline
Secondary Predicting Symptomatic CIPN: Changes in NF-L levels Changes in NF-L levels with chemotherapy used to predict development of symptomatic CIPN. NF-L measures will be summarized across time and analyzed using linear mixed effects model. Baseline and 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A